(ARGX) argenx - Ratings and Ratios
Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: US04016X1019
ARGX: Vygart, Vygart Hytrulo, Efgartigimod, Empasiprubart, Argx-119
argenx SE, a commercial-stage biopharmaceutical company, specializes in developing therapies for autoimmune diseases. Its lead products, VYGART and VYGART HYTRULO, are approved for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The companys pipeline includes efgartigimod, targeting multiple autoimmune conditions such as seronegative and ocular gMG, thyroid eye diseases, and lupus nephropathy. Other candidates like empasiprubart and ARGX-119 address rare neuromuscular disorders, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). The company also develops ARGX-112, ARGX-114, and ARGX-115, focusing on Galectin-10 and IL-6 pathways. argenx collaborates with multiple industry and academic partners, including AbbVie, LEO Pharma, and Genmab, to advance its research and development efforts.
Founded in 2008 and headquartered in Amsterdam, the company has built a diverse portfolio targeting autoimmune and rare diseases. Its strategic collaborations span biotech, pharmaceutical, and academic institutions, enhancing its R&D capabilities. The companys focus on novel mechanisms, such as targeting FcRn and IL-6, positions it as a key player in the autoimmune disease space. With a strong emphasis on innovation and partnerships, argenx continues to expand its pipeline and commercial footprint globally.
Additional Sources for ARGX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ARGX Stock Overview
Market Cap in USD | 33,314m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2017-05-18 |
ARGX Stock Ratings
Growth Rating | 90.7 |
Fundamental | 63.1 |
Dividend Rating | 0.0 |
Rel. Strength | 69.5 |
Analysts | 4.5/5 |
Fair Price Momentum | 702.45 USD |
Fair Price DCF | - |
ARGX Dividends
No Dividends PaidARGX Growth Ratios
Growth Correlation 3m | -86% |
Growth Correlation 12m | 87.1% |
Growth Correlation 5y | 92.2% |
CAGR 5y | 32.40% |
CAGR/Max DD 5y | 0.85 |
Sharpe Ratio 12m | 0.85 |
Alpha | 53.61 |
Beta | 0.242 |
Volatility | 42.75% |
Current Volume | 224.5k |
Average Volume 20d | 435.7k |
As of April 24, 2025, the stock is trading at USD 594.65 with a total of 224,496 shares traded.
Over the past week, the price has changed by +1.20%, over one month by -2.19%, over three months by -8.82% and over the past year by +58.54%.
Yes, based on ValueRay Fundamental Analyses, argenx (NASDAQ:ARGX) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 63.08 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARGX as of April 2025 is 702.45. This means that ARGX is currently undervalued and has a potential upside of +18.13% (Margin of Safety).
argenx has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy ARGX.
- Strong Buy: 13
- Buy: 7
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ARGX argenx will be worth about 759.5 in April 2026. The stock is currently trading at 594.65. This means that the stock has a potential upside of +27.72%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 786.9 | 32.3% |
Analysts Target Price | 674.5 | 13.4% |
ValueRay Target Price | 759.5 | 27.7% |